Galectin Therapeutics Stock Revenue
| GALT Stock | USD 1.04 0.96 48.00% |
Galectin Therapeutics fundamentals help investors to digest information that contributes to Galectin Therapeutics' financial success or failures. It also enables traders to predict the movement of Galectin Stock. The fundamental analysis module provides a way to measure Galectin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galectin Therapeutics stock.
| Last Reported | Projected for Next Year |
Galectin | Revenue |
Galectin Therapeutics Company Revenue Analysis
Galectin Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Galectin
Projected quarterly revenue analysis of Galectin Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Galectin Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Galectin Therapeutics' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Galectin Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Galectin Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Galectin Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galectin Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galectin Therapeutics could also be used in its relative valuation, which is a method of valuing Galectin Therapeutics by comparing valuation metrics of similar companies.Galectin Therapeutics is currently under evaluation in revenue category among its peers.
Galectin Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Galectin Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Galectin Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Galectin Therapeutics' value.| Shares | Cutter & Co Brokerage, Inc. | 2024-09-30 | 115.5 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 114.7 K | Sanctuary Advisors, Llc | 2024-06-30 | 100.7 K | Lpl Financial Corp | 2024-09-30 | 81.9 K | Susquehanna International Group, Llp | 2024-09-30 | 81.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 65.1 K | Retirement Guys Formula Llc | 2024-09-30 | 63.8 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 52.3 K | Horizon Asset Management Inc/ny | 2024-09-30 | 51.5 K | Vanguard Group Inc | 2024-09-30 | 2.1 M | Blackrock Inc | 2024-06-30 | 1.6 M |
Galectin Fundamentals
| Return On Equity | -37.28 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | 205.27 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Shares Owned By Insiders | 30.95 % | ||||
| Shares Owned By Institutions | 15.77 % | ||||
| Number Of Shares Shorted | 5.86 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (202 K) | ||||
| Net Income | (41.07 M) | ||||
| Cash And Equivalents | 15.83 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 71.81 M | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | (1.01) X | ||||
| Cash Flow From Operations | (32.97 M) | ||||
| Short Ratio | 42.37 X | ||||
| Earnings Per Share | (0.73) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 65.27 M | ||||
| Total Asset | 28.2 M | ||||
| Retained Earnings | (354.37 M) | ||||
| Working Capital | 12.03 M | ||||
| Current Asset | 26.4 M | ||||
| Current Liabilities | 1.36 M | ||||
| Net Asset | 28.2 M |
About Galectin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galectin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galectin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galectin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.